

LV Edge Packaging System

High titer, low cost lentivirus production



High performance

Routinely achieve E8 TU/mL titers for therapeutic transgenes and tune expression in the transduced cell.



Minimise GMP plasmid costs

Stable integration of viral genes into host cell reduces GMP plasmid requirements, leading to cost savings for every batch.




Lower supply chain risk

Requirement for just a single GMP plasmid lowers supply chain risk without compromising speed to market.

The LV Edge Packaging System is a semi-stable lentivirus production system **comprised** of:

- 1 A clonal, suspension-adapted cell line with viral genes under inducible control.
- 2 Sequence optimization to enhance potency of your Gene of Interest in the transduced cell.
- 3 Robust, ready-to-transfer processes and protocols across multiple scales.



How it works



We transfer

We transfer the LV Edge Packaging Cell Line to your lab.



You optimize

You optimize the sequence of your GOI using our advanced computational models.



We ship

We construct, prepare, sequence, QC, and ship your GOI transfer plasmid direct to your facility.




You manufacture

You transfect your GOI and manufacture lentivirus, receiving technical support from our team.

Choose the right system for you

	TRANSIENT	PACKAGING	PRODUCER
	4 plasmids <i>Transfection of viral and GOI plasmids</i>	1 plasmid <i>Transfection of GOI, induction of viral genes</i>	0 plasmid <i>Induction of viral genes and GOI</i>
Low cost	✗	✓	✓ ✓
Manufacturing complexity	✗	✓	✓ ✓
Low supply chain risk	✗	✓	✓ ✓
Scalability	✗	✗	✓
Development timeline	✓	✓	✗
Best for		Speed	Scale & reproducibility




Packaging system performance




Consistently achieves E8 TU/mL titers in clinical transgenes

Functional titer (unconcentrated harvest) following transfection of three CAR transgenes into LV Edge HEK293T packaging cell line.



Computer-aided optimization of your gene of interest

Sequence optimization shows up to 17x improvement in productivity for clinically relevant CAR, with consistent highest performance across multiple molecules versus competitors.



Visit www.asimov.com/LV to learn more